Bicycle Therapeutics Will Layoff 30% of Its Workers and “Deprioritize” an Antibody-Drug
Bicycle Therapeutics announced it will cut 30% of its workforce and “deprioritize” an experimental antibody–drug conjugate that had been seen as a potential competitor to Padcev, Pfizer’s bladder cancer drug. The decision follows discussions with the FDA and other regulators about the therapy’s approval pathway — a treatment known as zelenectide pevedotin. The company now expects a longer approval process than anticipated and has decided to push back development of this therapy that had been positioned as a rival to Pfizer’s drug.
